Articles

  • 1 month ago | tandfonline.com | Sunil Dogra |Sukhdeep Singh

    ABSTRACTIntroduction- Sonelokimab, a bispecific nanobody targeting interleukins (IL)-17A and IL-17F, has emerged as a novel therapeutic candidate for chronic inflammatory diseases such as psoriasis, hidradenitis suppurativa (HS), and psoriatic arthritis. Its innovative design offers improved tissue penetration, rapid clearance, and reduced immunogenicity, addressing limitations of current monoclonal antibody therapies.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →